Proliferative growth of the ventricular myocyte (cardiomyocyte) is primarily limited to fetal and early neonatal periods of development. In concert with the neonatal "transition" from proliferative to hypertrophic growth, ventricular remodeling of the nonmyocyte compartment is characterized by increased extracellular matrix synthesis/deposition and capillary angiogenesis. A role for locally generated and bioactive ventricular acidic fibroblast growth factor (aFGF) in these processes is proposed and substantiated by the following: 1) colocalization of aFGF peptide and fibroblast growth factor receptor (fig) transcripts to the developing fetal cardiomyocyte by immunohistochemistry, immunoelectron microscopy, and in situ hybridization, 2) continued localization of aFGF peptide and transcripts to the neonatal/mature cardiomyocyte, and 3) localization offig immunoreactivity and transcripts to specific neonatal ventricular nonmuscle cell types. Specific ventricular cell types at distinct developmental stages appear to be responsive to ventricular myocyte-derived aFGF (myocytes in the fetal heart and nonmyocytes/endothelial cells in the neonatal heart). These data indicate that expression of aFGF and one of its receptors (fig) are most pronounced in the fetal to early neonatal ventricle, the presence of both suggesting an autocrine/paracrine growth regulatory function. As the animal matures, ventricular capillary angiogenesis may be facilitated by "release" of cardiomyocyte-derived fibroblast growth factors into the surrounding extracellular space/matrix functioning as a "paracrine" angiogenic stimuli. Therefore, the results of our study suggest that myocyte-derived aFGF may function to increase the fetal ventricular cardiomyocyte population in absolute number as well as to facilitate the subsequent increase in capillary angiogenesis that occurs during cardiomyocyte maturation and ventricular remodeling. (Circulation Research 1993;72:7-19) KEY WoRDs * acidic fibroblast growth factor * fibroblast growth factor receptor * angiogenesis myocytes * growth factors G rowth and maturation of the ventricular myocyte (cardiomyocyte) are rapid processes that appear to be under partial control by locally generated growth factors. The expression of specific growth factors during fetal and neonatal periods of heart development may play distinct roles in initiating and modulating the proliferation and maturation of this unique cell type. Growth and development of the mammalian ventricle during the fetal and neonatal periods is, to a large extent, dependent on underlying changes occurring in the cardiomyocyte population. Cardiomyocyte growth in cell number in mammals is primarily limited to fetal periods of development.12 A limited number of studies have focused on any specific growth factors and/or their cognate receptors during the critical fetal to neonatal "transition" period of cardio-
G rowth and maturation of the ventricular myocyte (cardiomyocyte) are rapid processes that appear to be under partial control by locally generated growth factors. The expression of specific growth factors during fetal and neonatal periods of heart development may play distinct roles in initiating and modulating the proliferation and maturation of this unique cell type. Growth and development of the mammalian ventricle during the fetal and neonatal periods is, to a large extent, dependent on underlying changes occurring in the cardiomyocyte population. Cardiomyocyte growth in cell number in mammals is primarily limited to fetal periods of development.12 A limited number of studies have focused on any specific growth factors and/or their cognate receptors during the critical fetal to neonatal "transition" period of cardio-myocyte development. [3] [4] [5] [6] [7] [8] [9] [10] Composite analysis of the presence of both the peptide growth factor or associated transcript as well as the cognate receptor(s) or associated transcript are necessary to support the hypothesis of a specific autocrine/paracrine growth factor "loop" within a developing organ.
Subsequent increases in ventricular mass during the neonatal period are primarily the result of increased cellular size (hypertrophy) of a finite population of cardiomyocytes. Cardiomyocytes occupy the bulk of the heart tissue yet compose only 20-40% of the final total cellular populations of the ventricle.1' In addition, the ventricle of the neonate undergoes rapid tissue remodeling that is associated with capillary angiogenesis and the formation of an extensive extracellular matrix (ECM).2,12"3During this "transition" from fetal to neonatal development,'4,15 cardiomyocytes exit the cell cycle, complete additional rounds of DNA synthesis associated with the processes of binucleation and polyploidation, and begin their long-term maturational process of cellular hypertrophy. In concert with the terminal proliferative events in the cardiomyocyte population, the length and numbers of ventricular capillaries increase as the mechanisms of oxygen/nutrient exchange switch from diffusion in the fetal heart to vascular-mediated exchange in the maturing and adult myocardium.'617Although 8 Circulation Research Vol 72, No 1 January 1993 ventricular angiogenesis of the capillary network occurs primarily during neonatal development in rodents and humans, the stimulus or stimuli necessary for this angiogenic response remain to be determined. 16 Multiple stimuli may originate from the cardiomyocyte population of the maturing ventricle itself and function within the microenvironment of the growing vascular bed of the heart.
One specific well-defined angiogenic stimulus for the neonatal heart may be ventricular acidic fibroblast growth factor (aFGF),18 a peptide that is produced by the cardiomyocytes themselves.9"10'9-24 Cardiomyocyteproduced fibroblast growth factors cpm/,Lg DNA) probe. The probes used were cDNA inserts for aFGF cDNA29 and FGF receptor cDNA clones for the type 1 (flg) and type 2 (bek) forms. 30 The cDNA inserts were excised with the appropriate restriction endonucleases, purified by separation in a low-melt agarose gel, and random prime-labeled. The probes were added after boiling for 1 minute and immediately placed into an ice-water bath in a total volume of [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Itl to each sample. Samples were covered with a siliconized glass coverslip and incubated overnight. As a control for hybridization specificity, "cold" probe dilution studies were performed by adding increasing amounts of unlabeled cDNA inserts (20- bek-specific antisera were negative and presumed to be due to the lack of detectable expression of this form of the FGF receptor in the myocardium (data not shown).
Electron Microscopy and Immunogold Localization
Ventricular tissue was obtained from fetal pups at days 14-18 of gestation and neonatal pups at days 1-21, as previously described.7 Tissue samples were immersion-fixed in 4% paraformaldehyde containing 0.5% gluteraldehyde for 1 hour at 4°C. Fixed specimens were then processed and embedded in LR White or Lowicryl embedding media according to the manufacturers' directions. The LR White-embedded materials were polymerized for 48-72 hours under ultraviolet light at 4°C. All samples were "thin"-sectioned to gold interference thickness and mounted on formvar-coated zinc 300 mesh grids for subsequent processing. Sections werec i.
FIGURE 2. Photomicrographs showing immunoelectron microscopic localization of acidic fibroblast growth factor in fetal myocardium. Ventricular tissue was obtained from fetal Wistar-Kyoto rats (panels A and C) or spontaneously hypertensive rats (panels B and D-F) at 18 days of gestation, processed, embedded, sectioned, and stained as described in "Materials and Methods. " Nonspecific staining using normal rabbit serum was low to undetectable (panels A and B). Immunoreactivity was readily detected in both strains and was found primarily within the myocytes (panels C-F). The localization of the immunoreactivity was found in both the cytoplasmic (arrowheads), perinuclear (arrows), and occasional nuclear sites. Occasional labeling of the extracellular matrix (asterisk) was also seen (panels C and E). Bar, 0.5 gm. (Figure 1C) , the intensity and magnitude of the staining declines markedly, such that by 3-4 weeks of age ( Figure 1D change in immunoreactive intensity with ventricular maturation is consistent with a regulatory role for aFGF in both fetal and neonatal heart development.
To better localize the aFGF immunoreactivity to the myocytes and/or their surrounding ECM, immunoelectron microscopy was performed (Figures 2 and 3 ). In the fetal (day 18 of gestation) myocardium (Figure 2 ), prominent aFGF immunoreactivity was localized to the intracellular compartment of many myocytes ( Figures  2C-2F) , with both perinuclear and cytoplasmic regions heavily labeled. No prominent nuclear localization of aFGF immunoreactivity was noted. The labeling of the ECM in the fetal myocardium was noted ( Figure 2E ), yet it did not represent a major site of immunoreactivity. In the maturing 3-week-old neonatal myocardium (Figure 3) , the labeling index of the individual myocytes was less intense (Figures 3C and 3D) , far more infrequent, and yet often associated with perinuclear sites of biosynthesis. Extracellular sites of immunolabeling were seen with the ECM in the mature myocardium ( Figure  3D) .
Because of the temporal patterns determined for aFGF immunoreactivity in the fetal and neonatal heart, we wanted to determine by using in Figure 7D ). When the mature myocardium was examined (not shown), the adult myocyte and most nonmyocyte populations were generally devoid of aFGF hybridization signals, yet the continued presence of aFGF immunoreactivity and extractable FGF peptides, as shown by others,20'22'23 from the mature myocyte suggests that the level of aFGF transcripts may be below the limit of detection when either total RNA or in situ hybridizations are used.
FGF Receptors in the Fetal and Neonatal Myocardium
Analysis of the expression of the FGF receptors (fig and bek) in these two rat strains has been performed8 to determine whether FGF receptor expression pattern coincides with that of the development of the heart and is in any way coordinated with the expression of one of its ligands. The coincidental expression of both peptide growth factor and cognate receptor by the same or adjacent cellular population is a necessary prerequisite for an autocrine or paracrine growth regulatory paradigm to be proposed. In agreement with other studies, expression for flg returned to readily detectable levels that reached an additional "peak" between the fifth and seventh week of age. In the mature myocardium of the two strains examined, limited to undetectable expression was noted (not shown). There did not appear to be any major variations in transcript abundance when comparing SHR and WKY rats over the ages examined, although further analysis may be warranted during embryonic and fetal stages of development.
Localization of the ventricular cell type responsible for the flg expression pattern previously described8 was determined by both immunohistochemical and immunoelectron microscopic localization as well as in situ hybridization. Immunohistochemical studies using an antisera directed toward the extracellular COOH-ter- 4D ). Because the resolution of paraffin-embedded materials is limited, confirmation of the cellular localization of the immunoreactivity was extended by use of immunoelectron microscopy and in situ hybridization. Figure 5 shows the prominent subcellular immunoreactivity by immunoelectron microscopy of the fetal myocytes ( Figures 5A-5D) Figure 6A) . The Figure 6B ). In the 3-week-old myocardium ( Figure 6C ), labeling remained primarily on the nonmyocyte populations and was often found at high levels on and around major blood vessels, as previously shown histochemically ( Figure 4C ). In the mature myocardium ( Figure 6D ),flg expression was greatly reduced, and very limited expression was occasionally found in the nonmus- Figures 7C, 7E, and 7F ). In concert with this cell-type change in flg expression, limited transcript levels for aFGF could still be localized to the myocytes of the neonatal myocardium ( Figure 7D ). 
Discussion

